
Opinion|Videos|June 27, 2024
Plaque Psoriasis Case Study: Patient Presentation, Treatment Selection, and Shared Decision-Making for Improved Outcomes
The key opinion leaders examine a case study of a 42-year-old male patient, detailing the process of treatment selection and shared decision-making that led to improved outcomes.
Advertisement
Advertisement
Related to this article

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin
2
Monitoring and Treatment Selection for Oral TYK2 Inhibitors in Psoriasis
3
Bioelements and Celluma Collaborate on LED Facial Treatments
4
Aclaris' Bosakitug Misses Phase 2 Endpoints in Atopic Dermatitis
5


